Andreasen PA - Search Results

1

The plasminogen activation system in tumor growth, invasion, and metastasis.

Andreasen PA, Egelund R, Petersen HH. Andreasen PA, et al. Cell Mol Life Sci. 2000 Jan 20;57(1):25-40. doi: 10.1007/s000180050497. Cell Mol Life Sci. 2000. PMID: 10949579 Review.

2

Biochemical properties of plasminogen activator inhibitor-1.

Dupont DM, Madsen JB, Kristensen T, Bodker JS, Blouse GE, Wind T, Andreasen PA. Dupont DM, et al. Among authors: andreasen pa. Front Biosci (Landmark Ed). 2009 Jan 1;14:1337-61. doi: 10.2741/3312. Front Biosci (Landmark Ed). 2009. PMID: 19273134 Review.

3

Serum-stable RNA aptamers to urokinase-type plasminogen activator blocking receptor binding.

Dupont DM, Madsen JB, Hartmann RK, Tavitian B, Ducongé F, Kjems J, Andreasen PA. Dupont DM, et al. Among authors: andreasen pa. RNA. 2010 Dec;16(12):2360-9. doi: 10.1261/rna.2338210. Epub 2010 Oct 20. RNA. 2010. PMID: 20962041 Free PMC article.

4

Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue.

Usher PA, Thomsen OF, Iversen P, Johnsen M, Brünner N, Høyer-Hansen G, Andreasen P, Danø K, Nielsen BS. Usher PA, et al. Among authors: andreasen p. Int J Cancer. 2005 Mar 1;113(6):870-80. doi: 10.1002/ijc.20665. Int J Cancer. 2005. PMID: 15515049

5

Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.

Offersen BV, Pfeiffer P, Andreasen P, Overgaard J. Offersen BV, et al. Lung Cancer. 2007 Apr;56(1):43-50. doi: 10.1016/j.lungcan.2006.11.018. Epub 2007 Jan 17. Lung Cancer. 2007. PMID: 17207889

6

A specific plasminogen activator inhibitor-1 antagonist derived from inactivated urokinase.

Gong L, Proulle V, Fang C, Hong Z, Lin Z, Liu M, Xue G, Yuan C, Lin L, Furie B, Flaumenhaft R, Andreasen P, Furie B, Huang M. Gong L, et al. J Cell Mol Med. 2016 Oct;20(10):1851-60. doi: 10.1111/jcmm.12875. Epub 2016 May 20. J Cell Mol Med. 2016. PMID: 27197780 Free PMC article.

7

Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor.

Cubellis MV, Andreasen P, Ragno P, Mayer M, Danø K, Blasi F. Cubellis MV, et al. Proc Natl Acad Sci U S A. 1989 Jul;86(13):4828-32. doi: 10.1073/pnas.86.13.4828. Proc Natl Acad Sci U S A. 1989. PMID: 2544876 Free PMC article.

8

Epithelial glycoprotein-330 mediates endocytosis of plasminogen activator-plasminogen activator inhibitor type-1 complexes.

Moestrup SK, Nielsen S, Andreasen P, Jørgensen KE, Nykjaer A, Røigaard H, Gliemann J, Christensen EI. Moestrup SK, et al. J Biol Chem. 1993 Aug 5;268(22):16564-70. J Biol Chem. 1993. PMID: 8344937

9

Forskolin down-regulates type-1 plasminogen activator inhibitor and tissue-type plasminogen activator and their mRNAs in human fibrosarcoma cells.

Georg B, Riccio A, Andreasen P. Georg B, et al. Mol Cell Endocrinol. 1990 Aug 20;72(2):103-10. doi: 10.1016/0303-7207(90)90100-m. Mol Cell Endocrinol. 1990. PMID: 1704320

10

Suppression of Tumor Growth and Metastases by Targeted Intervention in Urokinase Activity with Cyclic Peptides.

Wang D, Yang Y, Jiang L, Wang Y, Li J, Andreasen PA, Chen Z, Huang M, Xu P. Wang D, et al. Among authors: andreasen pa. J Med Chem. 2019 Feb 28;62(4):2172-2183. doi: 10.1021/acs.jmedchem.8b01908. Epub 2019 Feb 15. J Med Chem. 2019. PMID: 30707839

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results